APDN — Applied DNA Sciences Income Statement
0.000.00%
Last trade - 00:00
- $5.83m
- $2.36m
- $13.37m
- 16
- 48
- 31
- 23
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.39 | 1.93 | 9.03 | 18.2 | 13.4 |
Cost of Revenue | |||||
Gross Profit | 4.51 | 1.21 | 4.93 | 5.05 | 5.53 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 15.8 | 14.5 | 23.1 | 32.1 | 24.3 |
Operating Profit | -10.4 | -12.5 | -14 | -14 | -11 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.62 | -13 | -14.3 | -8.27 | -10 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.63 | -13 | -14.3 | -8.27 | -10 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -8.62 | -13 | -14.3 | -8.27 | -9.95 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.93 | -13 | -14.3 | -8.38 | -9.95 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -8.8 | -3.32 | -1.81 | -0.934 | -0.761 |